QUAD Investment Management
VC Fund
Seoul, South Korea
QUAD Investment Management is a VC fund in Seoul focused on Biotechnology and Health Care. Established in 2009, QUAD is an independent investment manager overseeing approximately US$1.0 billion in equity assets (as of June 2019). Our clients range from institutional clients such as pension funds, endowments and family offices to individual parents and their children. All investment managers and key management being equity partners of thefirm, QUAD members are significant investors in the company, which we believe aligns our goals with the interests of our clients.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 24%
Last updated:
For AI agents: llms.txt
Industries QUAD Investment Management invests in
Stages QUAD Investment Management invests in
Countries QUAD Investment Management invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $847k–$23M
- Series B
- $4M–$80M
- Series C
- $15M–$75M
Investment Focus
Industry
- Biotechnology 8 (38%)
- Health Care 7 (33%)
- Medical 4 (19%)
- Therapeutics 4 (19%)
- Software 2 (10%)
Stage
- Series B 5 (24%)
- Series A 4 (19%)
- Series C 4 (19%)
- Series D 2 (10%)
- Seed 1 (5%)
Country
- South Korea 7 (33%)
- United States 6 (29%)
- Japan 1 (5%)
- Singapore 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Hosung Hwang
CEO
|
CEO | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir’s cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh’s world-class oncolytic virus and immunotherapy research programs. | $14M / Series A / Aug 19, 2026 | ||
| HoneyNaps develops a bio-signal monitoring device to treat sleep disorders. The platform of the company collects and analyzes data like body temperature, heart rate, breathing, and movement during sleep, specializing in AI-powered sleep diagnostics, bio-signal monitoring, and sleep disorder treatment solutions. Its flagship platform, SOMNUM,analyzes sleep data using deep-learning algorithms to help diagnose and predict sleep-related diseases. | $11.6M / Series B / May 24, 2024 | ||
NeoCannBio
|
NeoCannBio provides natural product processing facilities for generating new medications derived from natural goods and built a cannabinoid library of hemp, and medical cannabis. | Series B / Sep 26, 2023 | |
| Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $106.5M / Series E / Apr 25, 2023 | ||
| Good Food For Good operates as a food & lifestyle brand company. | $23M / Series A / Dec 05, 2022 | ||
| Avelos Therapeutics is a precision medicine company in the clinical stage that finds, creates, and sells targeted therapeutics. | $8M / Series A / Aug 22, 2022 | ||
| Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir’s cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh’s world-class oncolytic virus and immunotherapy research programs. | Series A / Mar 16, 2022 | ||
| Curiox is a bioinstrumentation company spun out of the Agency for Science, Technology, and Research (A*STAR) in Singapore. Curiox has become a leader in the development and commercialization of innovative assay platforms based on its expertise in surface chemistry and engineering. Curiox’s vision is to accelerate the progress of life sciences, drugdiscovery and diagnostics through the miniaturization and improved automation of bioassays. | $15M / Series C / Mar 16, 2022 | ||
| Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients toget better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective services for payors. | $125M / Post-IPO Equity / Dec 06, 2021 | ||
| Every day we flush precious information on our bodies down the toilet. Bisu helps people capture these data and lead healthier, happier lives. Our product is a home health lab that provides personalized advice to help you look, feel and perform at your best, through easy, accurate urine and saliva tests. We are graduates of HAX, the world'sleading hardware accelerator, and have won numerous awards including Johnson & Johnson Innovation, MedTech Innovator, the Edison Awards, UK Tech Rocketship Awards and the British Business Awards. At CES 2020 we won the IHS Markit Innovation Award and were named by CNET as one of the top health-tracking devices. | $3.3M / Seed / Oct 07, 2021 | ||
| See all 21 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does QUAD Investment Management invest in?
QUAD Investment Management invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 21 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is QUAD Investment Management's check size?
QUAD Investment Management typically joins rounds of $847k–$23M at Series A, $4M–$80M at Series B and $15M–$75M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds QUAD Investment Management participates in.
How do I contact QUAD Investment Management?
Public channels for QUAD Investment Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at QUAD Investment Management?
The team at QUAD Investment Management includes Hosung Hwang (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
